Proton Therapy for Esophageal Cancer

Esophagus Cancer Clinical Trial

Official title: A Phase II Trial of Proton Chemotherapy (PCT) for Resectable Esophageal or Esophagogastric Junction Cancer

Status Recruiting

Clinical Trial Summary

The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin /paclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemotherapy regimens have included cisplatin, usually in conjunction with 5-fluorouracil.

In designing the regimen, the investigators attempt to improve on the standard cisplatin/5-fluorouracil regimen in several ways. First, full-dose paclitaxel is added to the regimen. This agent has activity against advanced esophageal cancer and is also a potent radiosensitizer. Second, the substitution of carboplatin for cisplatin has resulted in reduced toxicity of various combination regimens similar to that used by CROSS trial and allows for easier administration in the outpatient setting.4 Third, for localized esophageal cancer, dose distribution patterns achievable with proton beam could potentially offer important clinical advantages relative to those achievable with x-rays (photons).19 Based on this, the investigators believe that this study should be conducted with the radiation modality that offers the best dosimetry achievable at our institution.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Esophageal Neoplasms
• Esophagus Cancer

• NCT number: NCT01684904
• Study type: Interventional
• Source: Loma Linda University
• Contact: Proton Referral Office First call: Referral Office intake person
• Phone: 909-558-4288 or 1 800 PROTONS
• Status: Recruiting
• Phase: N/A
• Start date: February 20, 2013
• Completion date: August 2032